Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAM NASDAQ:CNTA NASDAQ:IRON NASDAQ:IVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$20.60-4.4%$19.00$13.52▼$35.25$2.18B2.142.75 million shs2.44 million shsCNTACentessa Pharmaceuticals$21.81-3.8%$16.74$9.60▼$23.24$3.04B1.471.41 million shs1.30 million shsIRONDisc Medicine$59.82-0.8%$59.16$30.82▼$68.73$2.10B0.77279,542 shs178,558 shsIVAInventiva$5.61-2.8%$4.15$1.53▼$6.50$536.66M0.6971,042 shs128,196 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics-4.41%-1.34%+17.58%+20.75%-14.59%CNTACentessa Pharmaceuticals-3.79%+38.65%+27.25%+76.17%+58.62%IRONDisc Medicine-0.78%-1.55%-2.09%+11.38%+23.34%IVAInventiva-2.77%+0.72%+39.55%+64.52%+150.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$20.60-4.4%$19.00$13.52▼$35.25$2.18B2.142.75 million shs2.44 million shsCNTACentessa Pharmaceuticals$21.81-3.8%$16.74$9.60▼$23.24$3.04B1.471.41 million shs1.30 million shsIRONDisc Medicine$59.82-0.8%$59.16$30.82▼$68.73$2.10B0.77279,542 shs178,558 shsIVAInventiva$5.61-2.8%$4.15$1.53▼$6.50$536.66M0.6971,042 shs128,196 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics-4.41%-1.34%+17.58%+20.75%-14.59%CNTACentessa Pharmaceuticals-3.79%+38.65%+27.25%+76.17%+58.62%IRONDisc Medicine-0.78%-1.55%-2.09%+11.38%+23.34%IVAInventiva-2.77%+0.72%+39.55%+64.52%+150.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 3.08Buy$46.40125.24% UpsideCNTACentessa Pharmaceuticals 3.08Buy$32.7049.93% UpsideIRONDisc Medicine 3.09Buy$98.3064.33% UpsideIVAInventiva 2.83Moderate Buy$14.83164.41% UpsideCurrent Analyst Ratings BreakdownLatest IVA, IRON, BEAM, and CNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025CNTACentessa PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/3/2025CNTACentessa PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$31.009/3/2025IVAInventivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.009/2/2025IVAInventivaGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $13.008/29/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$40.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.008/18/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$85.00 ➝ $90.008/12/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.008/6/2025BEAMBeam TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$25.00 ➝ $21.007/30/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$60.27M34.58N/AN/A$8.86 per share2.33CNTACentessa Pharmaceuticals$6.85M426.36N/AN/A$3.05 per share7.15IRONDisc MedicineN/AN/AN/AN/A$14.85 per shareN/AIVAInventiva$9.20M58.35N/AN/A($1.21) per share-4.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$376.74M-$4.50N/AN/AN/A-661.31%-43.15%-31.06%11/4/2025 (Estimated)CNTACentessa Pharmaceuticals-$235.76M-$1.79N/AN/AN/AN/A-40.39%-29.87%11/11/2025 (Estimated)IRONDisc Medicine-$109.36M-$4.47N/AN/AN/AN/A-26.60%-24.58%11/11/2025 (Estimated)IVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/A9/25/2025 (Estimated)Latest IVA, IRON, BEAM, and CNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q2 2025IVAInventiva-$0.41N/AN/AN/AN/AN/A8/12/2025Q2 2025CNTACentessa Pharmaceuticals-$0.35-$0.38-$0.03-$0.38$0.63 millionN/A8/7/2025Q2 2025IRONDisc Medicine-$1.17-$1.58-$0.41-$1.58N/AN/A8/5/2025Q2 2025BEAMBeam Therapeutics-$1.04-$1.00+$0.04-$1.00$13.29 million$8.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam Therapeutics$0.904.37%N/AN/A N/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam TherapeuticsN/A6.756.75CNTACentessa Pharmaceuticals0.3210.1110.12IRONDisc Medicine0.0532.1132.11IVAInventivaN/A0.920.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%CNTACentessa Pharmaceuticals82.01%IRONDisc Medicine83.70%IVAInventiva19.06%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics3.50%CNTACentessa Pharmaceuticals7.09%IRONDisc Medicine3.64%IVAInventiva32.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510101.16 million97.62 millionOptionableCNTACentessa Pharmaceuticals200133.91 million124.42 millionOptionableIRONDisc Medicine3034.77 million33.50 millionNot OptionableIVAInventiva10095.66 million65.05 millionNot OptionableIVA, IRON, BEAM, and CNTA HeadlinesRecent News About These CompaniesInventiva (NASDAQ:IVA) Shares Gap Up - Time to Buy?September 12 at 1:20 PM | marketbeat.comAnalysts Offer Predictions for Inventiva FY2025 EarningsSeptember 7, 2025 | marketbeat.comInventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Up 188.0% in AugustSeptember 6, 2025 | marketbeat.comShort Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Increases By 188.0%September 6, 2025 | americanbankingnews.comBrokers Issue Forecasts for Inventiva FY2025 EarningsSeptember 6, 2025 | americanbankingnews.comInventiva (NASDAQ:IVA) Shares Gap Up Following Analyst UpgradeSeptember 5, 2025 | marketbeat.comInventiva (NASDAQ:IVA) Receives Buy Rating from HC WainwrightSeptember 5, 2025 | marketbeat.comInventiva to Participate in Upcoming September Investor ConferencesSeptember 4, 2025 | globenewswire.comInventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume After Analyst UpgradeSeptember 4, 2025 | marketbeat.comInventiva (NASDAQ:IVA) Given New $13.00 Price Target at GuggenheimSeptember 4, 2025 | marketbeat.comHC Wainwright Begins Coverage on Inventiva (NASDAQ:IVA)September 4, 2025 | americanbankingnews.comGuggenheim Boosts Inventiva (NASDAQ:IVA) Price Target to $13.00September 4, 2025 | americanbankingnews.comInventiva assumed with a Buy at H.C. WainwrightSeptember 4, 2025 | msn.comInventiva (NASDAQ:IVA) Shares Gap Up on Analyst UpgradeSeptember 4, 2025 | americanbankingnews.comInventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume Following Analyst UpgradeSeptember 3, 2025 | americanbankingnews.comInventiva (NASDAQ:IVA) Shares Gap Down - Time to Sell?August 31, 2025 | marketbeat.comInventiva (NASDAQ:IVA) Stock Rating Upgraded by Piper SandlerAugust 31, 2025 | marketbeat.comInventiva (NASDAQ:IVA) Hits New 12-Month High - What's Next?August 29, 2025 | marketbeat.comHow Much Upside is Left in Inventiva (IVA)? Wall Street Analysts Think 100.79%August 29, 2025 | zacks.comInventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesAugust 29, 2025 | marketbeat.comInventiva (NASDAQ:IVA) Trading 4.3% Higher - What's Next?August 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhat NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025New Age Warfare: Anduril Is the Hype, AeroVironment Is the BuyBy Jeffrey Neal Johnson | August 28, 2025What to Watch for From D-Wave Now That Earnings Are DoneBy Nathan Reiff | September 2, 2025Take the Money and Run: Strategy Stock Looks Tapped OutBy Gabriel Osorio-Mazilli | September 9, 2025Dueling Insider Moves: Heavy Buying Here, Big Selling ThereBy Leo Miller | September 2, 2025IVA, IRON, BEAM, and CNTA Company DescriptionsBeam Therapeutics NASDAQ:BEAM$20.60 -0.95 (-4.41%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$20.61 +0.01 (+0.05%) As of 09/12/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Centessa Pharmaceuticals NASDAQ:CNTA$21.81 -0.86 (-3.79%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$21.66 -0.15 (-0.71%) As of 09/12/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Disc Medicine NASDAQ:IRON$59.82 -0.47 (-0.78%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$59.82 0.00 (0.00%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Inventiva NASDAQ:IVA$5.60 -0.17 (-2.86%) As of 09/12/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
